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Abstract
Reduced bone toughness, the energy absorption capacity of the tissue, has been consistently
documented in vertebrae of animals treated with a wide range of bisphosphonate doses. Data
regarding toughness changes in the rib are conflicting with one report showing no effect and another
showing a significant reduction following treatment of beagle dogs with high doses of
bisphosphonates. The goal of this study was to evaluate changes in bone toughness and various other
tissue-level properties of the rib following three years of bisphosphonate treatment with doses at and
above those used to treat osteoporosis. Skeletally mature intact beagle dogs were treated daily for
three years with vehicle (VEH), alendronate 0.2 mg/kg/day (ALN0.2), or alendronate 1.0 mg/kg/day
(ALN1.0). The lower ALN dose approximates, on a mg/kg basis, that used for treatment of
postmenopausal osteoporosis with the higher dose being 5x higher. Ribs were assessed for
biomechanical properties, bone turnover rate, microdamage, density, and geometry. Toughness was
significantly lower with ALN1.0 (-33%), but not ALN0.2 (-19%), compared to VEH while neither
ultimate stress nor modulus differed among groups. Bone density, geometry, and structural
biomechanical properties were similar among the three groups. There was no significant difference
in overall microdamage accumulation among groups. Intracortical bone formation rate was
significantly lower than VEH in both ALN groups (-69 to -90%). These data show that while rib
cortical bone experiences significant reductions in turnover following bisphosphonate treatment, it
is only in animals treated with doses above those used to treat osteoporosis that toughness is
significantly compromised.
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Introduction
Reduced bone toughness, the energy absorption capacity of the tissue, has been consistently
documented in the vertebrae of beagle dogs treated with bisphosphonates. Following one year
of treatment at doses equivalent to or below those used to treat postmenopausal osteoporosis,
bisphosphonates non-significantly reduced (-6 to -20%) vertebral bone toughness [1]; higher
doses significantly reduced vertebral toughness (-21%) [2]. Bisphosphonate treatment for three
years significantly reduced vertebral toughness compared to vehicle-treated controls at doses
both equivalent to (-27%) and above (-30 to -40%) those used to treat patients with osteoporosis
[3,4].
Less is known regarding how bisphosphonate treatment affects toughness at other skeletal sites.
Specifically, data regarding bisphosphonate-induced changes in bone toughness at the rib, a
primarily cortical bone site that undergoes appreciable amounts of bone remodeling and is at
risk for osteoporotic fracture, are conflicting. Significant reductions in toughness (-20%) of
ribs from beagle dogs were shown after one year of alendronate treatment at doses exceeding
those used clinically for postmenopausal osteoporosis [5]. In contrast, following three years
of high dose incadronate treatment, no significant difference in rib toughness was shown
between treated and non-treated animals [6]. Although these latter data were touted in an
editorial to point to a new ‘vista’ with respect to the negative effects of bisphosphonates on
material properties [7], in actuality the manner in which toughness was calculated in these two
papers was significantly different. In three point bending tests, the load-deformation curve
describes forces and moments that can be used to depict stresses and strains. This is achieved
via transformation of the load-deformation curve into a stress-strain curve using standard
engineering equations that incorporate calculations based on the dimensions of the sample
rather than use direct values. This stress-strain curve can be broken down into pre-yield and
post-yield portions (Figure 1). Pre-yield toughness represents the area under the stress/strain
curve up to the point of yield, which is where permanent deformation of the bone has occurred
while post-yield toughness represents the area under the curve between the yield point and
fracture. In these rib bending tests, there exists a significant amount of displacement between
the point of yield and the eventual fracture. Mashiba et al. defined toughness as the area under
the stress-strain curve to fracture, therefore encompassing both pre-yield and post-yield regions
[5]. Komatsubara et al. defined toughness as the area under the stress-strain curve to ultimate
stress [7]. Given that yield and ultimate stress are nearly identical in these rib three point
bending tests, the values reported by Komatsubara reflect mainly the pre-yield portion of the
curve. Whether the different approaches to defining toughness fully explain these contrasting
results is unclear.
The goal of this study was to evaluate differences in bone toughness, along with various other
properties of the rib, following three years of daily alendronate treatment at doses equivalent
to and above those used for treatment of post menopausal osteoporosis. We hypothesized that
alendronate would reduce bone toughness at doses equal to and above those used clinically to
treat osteoporosis, and that these changes would be associated with suppression of bone
remodeling and accumulation of microdamage.
Materials and Methods
Experimental Design
Details of the experimental design have been previously published [3]. All procedures were
approved by the Indiana University School of Medicine Animal Care and Use Committee.
Female beagles (1-2 yrs old; n=36) were confirmed to be skeletally mature (closed proximal
tibia and lumbar vertebra growth plates on x-ray) prior to the start of the study. Animals were
treated daily for three years with oral doses of vehicle (VEH, 1 ml/kg/day saline) or alendronate
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(0.2, or 1.0 mg/kg/day, Merck and Co., Inc., Rahway, NJ). The 0.2 mg dose corresponds, on
a mg/kg basis, to those used for treatment of post-menopausal osteoporosis while the 5x higher
dose was chosen to match previous studies. Alendronate was mixed in saline as either a 0.05%
solution (0.2 mg dose) or a 0.2% solution (1.0 mg dose) with a correction for the 16.4% moisture
content. Appropriate amounts of the alendronate solution were supplemented with saline to
reach a total volume of 10 mL for each daily dose. Dogs were administered alendronate, or a
saline vehicle, with a syringe each morning after an overnight fast and at least 2 hours prior to
feeding. Prior to necropsy, animals were injected with calcein (5 mg/kg as a 3% solution, IV)
using a 2-12-2-5 labeling schedule to allow measurement of dynamic histomorphometry.
Following three years of treatment, animals were euthanized by intravenous administration of
sodium pentobarbital (0.22mg/kg Beuthanasia-D Special). The mid-portion of the ninth right
rib was saved in 70% ethanol for assessment of microdamage while an adjacent portion was
saved in 10% neutral buffered formalin for dynamic histomorphometry measurements. The
left eleventh rib was wrapped in saline-soaked gauze and frozen (-20°C) for later measures of
density, geometry, and mechanical testing.
Density and geometry
Volumetric bone density and geometry were quantified using a Norland Stratec XCT Research
SA+ pQCT (Stratec Electronics). Prior to scanning, the point of greatest curvature on each rib
(approximately mid-rib) was marked with a pencil and portions of the bone >20 mm from this
point were removed (remaining specimen was 40 mm in total length). A single bone slice was
imaged at the mid-point using a scanning resolution of 0.07 × 0.07 × 0.50 mm. Total bone
mineral content (BMC, mg/mm), total volumetric bone mineral density (vBMD, mg/cm3),
cross-sectional area (CSA, mm2), anterior-posterior diameter (APdia, mm) and cross-sectional
moment of inertia (CSMI, mm4) were obtained using standard scanner software. CSMI values
were calculated in the plane perpendicular to the axis of 3-point bending.
Histomorphometry (Dynamic and microdamage)
Ribs were processed separately for assessment of microdamage or fluorochrome labels.
Specimens for microdamage analyses were stained en bloc with 1% basic fuchsin and then
embedded undecalcified in methyl methacrylate [5]. Specimens for assessment of
fluorochrome labels were embedded undecalcified in methyl methacrylate [8]. Two serial
semi-thin sections (~80-100 μm) were cut from both stained and unstained ribs using a diamond
wire saw (Histosaw; Delaware Diamond Knives). The unstained and bulk stained regions of
assessment were ~ 5 mm apart. Microdamage and fluorochrome labels were assessed using a
semiautomatic analysis system (Bioquant OSTEO 7.20.10, Bioquant Image Analysis Co.)
attached to a microscope equipped with an ultraviolet light source (Nikon Optihot 2
microscope, Nikon). Measurements were carried out on one unstained (dynamic), and two bulk
stained (microdamage) sections per animal. Analysis of two sections for microdamage
assessment reduces the probability of not finding any cracks in a given specimen [9]. Dynamic
histomorphometric measures included separate assessment of fluorochrome labels on the
periosteal, endocortical/trabecular, and intracortical bone envelopes [8]. All variables were
measured and calculated in accordance with ASBMR recommended standards [10].
Microdamage in the cortex of the rib (excluding trabecular bone) was assessed using UV
fluorescence [1]. Measures included crack length (Cr.Le) and crack number (Cr.N) and
calculations of crack density (Cr.Dn; Cr.N / bone area) and crack surface density (Cr.S.Dn;
Cr.N * Cr.Le / bone area).
Biomechanical tests
Three-point bending was conducted in accordance with our previously described method [5]
using a material testing machine (Alliance RT/5, MTS Systems Corp., Eden Prairie, MN,
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USA). After thawing to room temperature, specimens were placed on a three-point bending
fixture (bottom support span = 25 mm) with the convex surface of the rib facing up. The upper
support contact point was at the mid-point of the specimen, matching the site of pQCT analyses.
Bones were soaked with PBS prior to starting the test. Specimens were loaded to failure at a
displacement rate of 20 mm/min and load versus displacement data were collected at 10 Hz.
Structural mechanical properties, ultimate load, stiffness, displacement, and energy absorption
were determined from the load-deformation curves using standard definitions [5,11]. Material-
level properties, ultimate stress (σult), modulus (E), and toughness (u), were calculated by
normalizing the structural parameters as follows:
where L represents the bottom support span of the testing fixture (25 mm) and APdia and CSMI
are from pQCT scans. Displacement, energy absorption, and toughness parameters were
calculated for the entire test (to fracture) as well as separately for the pre-yield and post-yield
portions of the curve with the yield point defined using the 2% offset criterion [11]. Equations
used to calculate material properties are identical to those used previously for testing dog ribs
via three-point bending [5,6].
Statistics
All statistical tests were performed using SAS software (SAS Institute, Inc.). Differences
among the three treatment groups were evaluated using a one-way analysis of variance
(ANOVA). When a significant overall F value (p ≤ 0.05) was present, differences between
individual group means were tested using Fisher’s protected least-significant difference
(PLSD) post-hoc test. For all tests, p ≤ 0.05 was considered significant. All data are presented
as mean ± standard error.
Results
Toughness was significantly lower after three years of treatment with ALN1.0 (-33%), but not
ALN0.2 (-19%), compared to VEH-treated animals (Figure 2). Specifically, there was a
significant reduction in post-yield toughness with no difference among the three groups in pre-
yield toughness (Table 1). Neither ultimate stress nor modulus differed among the three groups.
At the structural level, there was no significant difference among groups for ultimate load,
stiffness, or energy to failure (Table 1). The ribs of animals treated with ALN1.0 had
significantly reduced post-yield displacement (-20%) compared to VEH, consistent with the
reductions in post-yield toughness, with no difference in pre-yield displacement (Table 1).
There was no difference in bone mineral content, volumetric bone density, or cross-sectional
moment of inertia among the three treatment groups (Table 1).
Bone formation rate (BFR/BS) on the endocortical/trabecular bone surface of alendronate-
treated animals was significantly lower (-59% ALN0.2; -75% ALN1.0) compared to vehicle
(Table 2). This reduction in BFR was the result of significant reductions in mineralizing surface
(MS/BS) in both ALN groups with no significant difference in mineral apposition rate (MAR)
among the groups. There was no difference in BFR on the endocortical/trabecular surface
between the two doses of ALN. Suppression of BFR also occurred within the intracortical bone
envelope, with both ALN0.2 (-90%) and ALN1.0 (-69%) having lower bone formation rates
compared to VEH (Figure 2). Neither intracortical MAR nor labeled osteon number (a
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surrogate of MS/BS for the intracortical envelope) were significantly different among groups
(Table 2), nor was there a difference between the two ALN doses for any intracortical turnover
parameters. On the periosteal surface MS/BS was significantly higher in ribs of ALN0.2-treated
animals compared to VEH and ALN1.0. Neither periosteal MAR nor BFR were different
among the three groups.
There was no significant difference in microdamage accumulation (crack number, crack
density, or crack surface density) within the cortical bone of the rib among the three treatment
groups (Figure 2, Table 2). Mean crack length was significantly higher (+23%) in both ALN0.2
and ALN1.0 groups compared to VEH.
Discussion
The toughness of bone relates to its capacity to absorb energy and resist fracture. Data from
biomechanical tests performed on the vertebrae of beagle dogs treated with bisphosphonates
[1-4] consistently indicate that there is a reduction in toughness. However, reports of
bisphosphonate-induced changes in rib toughness have thus far been discordant [5,6].
Specifically, previous analyses of ribs from bisphosphonate-treated dogs showed significant
reductions in toughness compared to vehicle-treated animals at one year using alendronate at
doses 5x the clinical dose for osteoporosis, but not at three years using incadronate at 2.5x or
5x the clinical dose. The current study assessed changes in rib toughness, as well as other
properties of the rib tissue, following three years of alendronate treatment at doses equivalent
to or above those used for treatment of postmenopausal osteoporosis. We show that only
animals treated with doses of alendronate 5x higher than those used for treatment of
postmenopausal osteoporosis have significantly compromised toughness of the rib.
An important difference exists in the how the parameter of toughness was defined in previous
studies that assessed rib biomechanical properties. One study revealed significant reductions
in toughness following one year of alendronate treatment (using the same high dose used in
the current study) and defined toughness as the area under the stress-strain curve to fracture
[5]. Results of a subsequent study, in which the ribs from animals treated with high doses of
incadronate (2.5x or 5x higher than the dose used for post-menopausal osteoporosis) showed
no difference in toughness compared to controls, toughness was defined as the area under the
stress-strain curve to ultimate stress [6]. As the yield and ultimate points are nearly identical
in these three-point bending tests, energy absorption to ultimate stress reflects mainly the pre-
yield portion of the curve. In these bending tests, the majority of energy absorption occurs in
the post-yield region as is evident in the current experiment which demonstrated that >85% of
toughness was contained in the post-yield region (Table 1). Based on this, it is likely that
considering only the pre-yield region does not permit the detection of changes in rib toughness
with bisphosphonate treatment. We demonstrate that there were no significant treatment-
related differences in pre-yield toughness of the ribs and that the significant reduction in overall
toughness (the energy absorption to fracture) can be attributable to reductions in post-yield
toughness. While the clinical relevance of changes in pre- and post-yield toughness has not
been clearly defined, it is generally considered that reductions in post-yield toughness
compromise the ability to withstand an impact without fracture [11,12].
While toughness of the rib was significantly lower than vehicle-treated controls in animals
treated with the higher dose of alendronate (-33%), it was not significantly different at doses
equivalent, on a mg/kg basis, to those used for treatment of postmenopausal osteoporosis (-19%
compared to vehicle). It is worth noting that while the higher dose of alendronate used in this
study approximates that used for Paget’s disease (our dose is about 25% higher on a mg/kg
basis), our dosing schedule (daily for three years) exceeds that used clinically. While our data
suggests a potential dose-dependent reduction in toughness, there was no significant difference
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when comparing the two alendronate doses. Despite reductions in toughness with the higher
dose of alendronate, there was no significant effect on rib ultimate stress or modulus, pre-yield
measures of material strength and stiffness, respectively. This is consistent with previous
reports [5,6] and suggests a specific effect of bisphosphonates on post-yield properties.
Furthermore, there was no significant effect of alendronate treatment on the extrinsic properties
of strength, stiffness, or energy absorption. This indicates that while the higher dose of
alendronate does not affect the biomechanical integrity of the rib as a structural unit, probably
because of the 13% greater BMC and 6% larger CSMI, the biomechanical properties of the
material are likely compromised. This is similar to the changes in structural versus material
properties that occur in vertebrae as a result of bisphosphonate treatment [3,13].
Consistent with previous reports, we found significantly lower levels of bone remodeling on
the endocortical/trabecular surfaces of ribs from animals treated with alendronate compared
to vehicle. After one year of alendronate treatment, the bone formation rate on this bone surface
was 75% lower than vehicle for the lower alendronate dose (0.2 mg) [8] and 78% lower with
the higher alendronate dose (1.0 mg) [5]. Interestingly, the absolute level of bone formation
on this surface after three years (6.7 μm3/μm2/day for ALN0.2 and 4.4 μm3/μm2/day for
ALN1.0) were nearly identical to the levels after one year (6.5 μm3/μm2/day for ALN0.2 and
3.2 μm3/μm2/day for ALN1.0) [5,8]. This suggests a lower limit of turnover suppression on
the endocortical/trabecular bone surface of the rib which is maximal within the first year of
treatment. Data from iliac crest biopsies of humans treated with bisphosphonates support the
idea of a lower limit, with similar levels of turnover suppression on trabecular/endocortical
surfaces in patients treated for 22 and 34 months with ibandronate [14]. Systemic lower limits
of turnover suppression have also been noted in numerous studies of serum/urine biomarkers
from patients treated with bisphosphonates [15].
The dynamics of remodeling suppression with bisphosphonates differ within the intracortical
envelope of the rib. One year of treatment at the lower dose of alendronate (ALN0.2) did not
significantly reduce intracortical turnover of the rib [8], while three years reduced the rate by
90% (Figure 2). Following one year of high-dose alendronate treatment (ALN1.0), intracortical
turnover was reduced by 72% compared to controls [5], while the current study shows a 69%
lower turnover after three years compared to controls. These data suggest that changes within
the intracortical envelope of the rib are dependent on treatment duration and are slower to
manifest with doses that are equivalent to those given clinically for treatment of
postmenopausal osteoporosis compared to higher doses.
The overall level of microdamage was not significantly different among the three treatment
groups; although significantly higher levels of microdamage in the rib were observed following
one year of treatment with the higher dose of alendronate [5]. We interpret these data as
suggesting the accumulation of damage is greatest during the early periods of bisphosphonate
treatment, and subsequently achieves a new balance at the lower remodeling rate by three years.
This is consistent with the kinetics of microdamage accumulation in the vertebrae that have
been described previously in these same animals [3]. Also consistent with the results from the
vertebra of these same animals is the finding that changes in toughness associated with
bisphosphonate treatment are not congruent with changes in microdamage accumulation. There
was a significant reduction in toughness (-33%) despite the absence of any significant
difference in microdamage between animals treated with vehicle and those treated with the
higher dose of alendronate. While it remains possible that microdamage may contribute to a
portion of the changes in toughness with bisphosphonate treatment, there is a clear need to
begin exploring how other changes in the tissue (e.g. changes to both the inorganic and the
organic fractions of bone) contribute to the reduction in bone toughness following
bisphosphonate treatment.
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In conclusion these data show that while cortical bone sites undergo significant reductions in
turnover in response to bisphosphonate treatment, it is only animals treated with doses that
exceed those used for treatment of post menopausal osteoporosis in which toughness is
significantly compromised. Furthermore, these results suggest that microdamage is unlikely a
primary factor contributing to reductions in bone toughness with bisphosphonate treatment.
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Figure 1.
Schematic of mechanical test plot from three-point bending test of dog rib. Load versus
deformation data from tests are converted to stress and strain, respectively, using standard
equations (see methods for equations). In these tests, the yield stress and ultimate stress are
nearly identical, while there is a considerable amount of displacement (strain) between these
points and the point of fracture. In the current study, toughness (the area under the stress/strain
curve) was quantified fracture (total area under the curve). We also separated the area under
the curve into pre-yield toughness (area of the curve to ultimate stress, lightly shaded region)
and post-yield toughness (area under the curve between ultimate stress and fracture, darkly
shaded region). Previous analyses by Komatsubara [6] assessed toughness only to the point of
ultimate stress.
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Figure 2.
Bone remodeling, microdamage accumulation, and toughness of rib cortical bone following
three years of treatment with vehicle or alendronate (ALN). (A) Intracortical bone formation
rate was significantly lower than vehicle in both ALN-treated groups while there was no
difference between the two ALN doses (ANOVA p = 0.008). (B) Crack surface density, an
index of microdamage accumulation representing the product of crack number and crack length
normalized to bone area, was not significantly different from VEH with either dose of ALN
(ANOVA p = 0.157). (C) Toughness, the energy absorption capacity to fracture, was
significantly lower than VEH with ALN1.0 (-33%), but not with ALN0.2 (-19%) (ANOVA p
= 0.023). Data expressed as mean ± SE. *p < 0.05 versus vehicle.
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Table 1
Rib density, geometry, and mechanical properties.
Vehicle Alendronate 0.2 mg/kg/day Alendronate 1.0 mg/kg/day P value
vBMD, mg/cm3 1199 ± 10 1201 ± 11 1209 ± 9 0.768
BMC, mg/mm 8.48 ± 0.31 9.37 ± 0.41 9.58 ± 0.66 0.243
CSMI, mm4 10.30 ± 0.93 11.66 ± 1.60 10.90 ± 1.67 0.799
Ultimate load, N 137 ± 8 142 ± 12 142 ± 14 0.950
Stiffness, N/mm 170 ± 9 184 ± 15 178 ± 21 0.801
Pre-yield displacement, mm 0.77 ± 0.01 0.78 ± 0.01 0.80 ± 0.02 0.343
Post-yield displacement, mm 4.73 ± 0.32 4.14 ± 0.26 3.30 ± 0.32 * 0.008
Energy to failure, mJ 596 ± 55 568 ± 58 474 ± 54 0.283
Ultimate stress, MPa 168 ± 10 154 ± 8 159 ± 7.8 0.514
Modulus, MPa 5601 ± 318 5524 ± 320 5678 ± 407 0.953
Pre-yield toughness, MJ/m3 3.2 ± 0.3 2.9 ± 0.2 2.9 ± 0.2 0.505
Post-yield toughness, MJ/m3 24.2 ± 2.5 19.6 ± 1.6 16.0 ± 1.6 * 0.019
Data are mean ± SE. p values refer to a one-way ANOVA among the three groups.
*
p < 0.05 versus Vehicle.
vBMD, volumetric bone mineral density; BMD, bone mineral content; CSMI, cross-sectional moment of inertia.
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Table 2
Envelope-specific bone formation activity and intracortical microdamage.
Vehicle Alendronate 0.2 mg/kg/day Alendronate 1.0 mg/kg/day P value
Periosteal
 MAR, μm/day 1.09 ± 0.33 0.94 ± 0.17 0.41 ± 0.26 0.178
 MS/BS, % 2.8 ± 0.9 5.8 ± 1.3 *† 1.6 ± 0.6 0.012
 BFR, μm3/μm2/day 6.6 ± 1.7 6.5 ± 1.3 2.3 ± 1.6 0.152
Endocortical/Trabecular
 MAR, μm/day 0.86 ± 0.07 0.83 ± 0.07 0.80 ± 0.13 0.904
 MS/BS, % 13.8 ± 1.9 6.4 ± 1.5 * 3.6 ± 0.9 * <0.001
 BFR, μm3/μm2/day 12.1 ± 2.0 6.7 ± 1.7 * 4.4 ±1.6 * 0.019
Intracortical
 MAR, μm/day 0.82 ± 0.12 0.31 ± 0.17 0.66 ± 0.16 0.067
 L.On.N, #/mm2 0.63 ± 0.12 0.24 ± 0.10 0.46 ± 0.18 0.148
 Crack number, # 5.6 ± 1.6 9.4 ± 1.5 8.1 ± 0.9 0.171
 Mean crack length, μm 58.9 ± 3.5 72.7 ± 2.2 * 73.4 ± 3.4 * 0.004
 Crack density, #/mm2 0.39 ± 0.11 0.60 ± 0.10 0.55 ± 0.08 0.305
Data are mean ± SE. p values refer to a one-way ANOVA among the three groups.
*
p < 0.05 versus Vehicle;
†
p < 0.05 versus ALN1.0. MAR, mineral apposition rate;
MS/BS, mineralizing surface per bone surface; BFR, bone formation rate; L.On.N, labeled osteon number.
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